Brexucabtagene Autoleucel in R/R Mantle Cell Lymphoma
Experts discussed the ZUMA-2 clinical trial of brexucabtagene autoleucel.
Liso-Cel's Efficacy in R/R Large B-Cell Lymphoma: Michael Wang, MD
The professor from University of Texas MD Anderson Cancer Center discussed the FDA approval of lisocabtagene maraleucel.
The Need for Academic and Community Collaboration With CAR T-Cell Therapy: Bijal Shah, MD; Michael Wang, MD
The hematologists from Moffitt Cancer Center and MD Anderson Cancer Center discussed the need for collaboration between academic and community practices for patients who receive CAR T-cell therapy.
Challenges in Managing High-Risk Mantle Cell Lymphoma: Bijal Shah, MD; Michael Wang, MD
The hematologist from Moffitt Cancer Center and MD Anderson Cancer Center discussed CAR T-cell therapy and other treatment options for MCL.
Navigating CAR T-Cell Therapy Referrals: Bijal Shah, MD; Michael Wang, MD
The hematologists from Moffitt Cancer Center and University of Texas MD Anderson Cancer Center discussed navigating the referral process for CAR T-cell therapy in hematologic malignancies.
Managing CAR T-Associated Neurotoxicity and CRS: Bijal Shah, MD, MS; Michael Wang, MD
The hematologists from Moffitt Cancer Center and MD Anderson discussed managing CAR T-cell therapy-associated toxicities.
CAR T-Cell Therapy Associated Toxicities: Bijal Shah, MD, MS; Michael Wang, MD
The hematologists from Moffitt Cancer Center and The University of Texas MD Anderson Cancer Center discussed CAR T-associated toxicities.
Dr. Wang on Future Research With CAR T-Cell Therapy in MCL
Michael Wang, MD, discusses the importance of additional CAR T-cell therapy research in mantle cell lymphoma.
Dr. Wang on the Safety Profile of Brexucabtagene Autoleucel in Relapsed/Refractory MCL
Michael Wang, MD, discusses the safety profile of the CAR T-cell therapy brexucabtagene autoleucel in relapsed/refractory mantle cell lymphoma.
Dr. Wang on the Impact of KTE-X19 on Outcomes in Higher- Versus Lower-Risk MCL
Michael Wang, MD, discusses the safety and effectiveness of the autologous anti-CD19 CAR T-cell therapy KTE-X19 in patients with higher- versus lower-risk mantle cell lymphoma.
Dr. Wang on the Utility of CAR T-Cell Therapy in Relapsed/Refractory MCL
Michael Wang, MD, discusses the utility of CAR T-cell therapy in relapsed/refractory mantle cell lymphoma.
Dr. Wang on Unique Properties of KTE-X19 in Relapsed/Refractory MCL
Michael Wang, MD, discusses unique properties of the investigational CAR T-cell therapy KTE-X19 in relapsed/refractory mantle cell lymphoma.
Dr. Wang on the Safety Profile of KTE-X19 in MCL
Michael Wang, MD, discusses the safety profile of the CAR T-cell therapy KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, according to results from the phase II ZUMA-2 trial.
Dr. Wang on CAR T-Cell Therapy Resistance in MCL
Michael Wang, MD, discusses CAR T-cell therapy and triple-resistance in mantle cell lymphoma.
Dr. Wang on Combatting CAR T-Cell Therapy Resistance in MCL
Michael Wang, MD, discusses resistance to CAR T-cell therapy and the next steps to overcoming this challenge in treatment for mantle cell lymphoma.
